Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

FDA Could Approve Magic Mushroom Chemical for Depression

Two Phase III trials showed synthetic psilocybin significantly improved treatment-resistant depression symptoms with rapid response and favorable safety, Compass Pathways said.

Summary by Quartz
Compass Pathways' proprietary form of psilocybin has passed a pair of clinical trials, sending stock upwards

2 Articles

QuartzQuartz
Center

FDA could approve magic mushroom chemical for depression

Compass Pathways' proprietary form of psilocybin has passed a pair of clinical trials, sending stock upwards

·United States
Read Full Article
GizmodoGizmodo
Lean Left

Magic Mushroom Ingredient Passes Major Test, Paving Way for FDA Approval

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Gizmodo broke the news in United States on Wednesday, February 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Psychedelics icon

Psychedelics

Stock Markets icon

Stock Markets

United States icon

United States

US Economy icon

US Economy

Business & Markets icon

Business & Markets

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal